Oct 28 (Reuters) - AMAG Pharmaceuticals (AMAG.O) found potential safety issues with its key kidney drug Feraheme, which reported declining sales, and said it will cut about a fourth of its workforce, sending the stock crashing 25 percent in extended trade.
